Xconomy: Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation
Summary
Qualcomm-Novartis Deal Portends Wave of Clinical Trial Innovation Xconomy San Diego — The significance of a deal announced last week during the 2015 International CES in Las Vegas went largely unnoticed amid the hubbub of the world’s biggest consumer technology show, packed as it was with 3,600 exhibitors and over 170,000 attendees.Under their partnership, Novartis is now using 2net, Qualcomm Life’s proprietary wireless connectivity platform, to collect and aggregate patient data during clinical trials.What it means is that clinical trials are emerging as the first multi-billion dollar global market for wearable health trackers and related technologies—and big pharmas are the primary customer.It’s huge,” says Patrick, who also serves as director of the Center for Wireless and Population Health Systems at the Qualcomm-endowed California Institute of Telecommunications and Information Technology (Calit2).The list of startups angling to provide patient data to pharmaceutical companies includes San Francisco-based Ginger.io, which recently raised $20 million in new funding to advance its predictive analytics technology for healthcare, and Quanttus, a Cambridge, MA-based startup developing a wearable wrist sensor for clinical data collection and analysis.
Classifications
AskAI Classifications
LabelsLinked Companies
